EA201690199A1 - Лекарственное средство для лечения неалкогольной жировой болезни печени - Google Patents

Лекарственное средство для лечения неалкогольной жировой болезни печени

Info

Publication number
EA201690199A1
EA201690199A1 EA201690199A EA201690199A EA201690199A1 EA 201690199 A1 EA201690199 A1 EA 201690199A1 EA 201690199 A EA201690199 A EA 201690199A EA 201690199 A EA201690199 A EA 201690199A EA 201690199 A1 EA201690199 A1 EA 201690199A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
drug
liver disease
fatty liver
alcoholic fatty
Prior art date
Application number
EA201690199A
Other languages
English (en)
Inventor
Харуки Сибата
Тосиаки Такидзава
Original Assignee
Кова Компани, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кова Компани, Лтд. filed Critical Кова Компани, Лтд.
Publication of EA201690199A1 publication Critical patent/EA201690199A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В данном изобретении представлено соединение, применяемое для профилактики и лечения неалкогольной жировой болезни печени. Изобретение относится к лекарственному средству для профилактики и/или лечения неалкогольной жировой болезни печени, где лекарственное средство содержит в качестве активного ингредиента (R)-2-[3-[[N-(бензоксазол-2-ил)-N-3-(4-метоксифенокси)пропил]аминометил]фенокси]масляную кислоту, ее соль или ее сольват.
EA201690199A 2013-07-10 2014-07-09 Лекарственное средство для лечения неалкогольной жировой болезни печени EA201690199A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013144643 2013-07-10
PCT/JP2014/068253 WO2015005365A1 (ja) 2013-07-10 2014-07-09 非アルコール性脂肪性肝疾患治療剤

Publications (1)

Publication Number Publication Date
EA201690199A1 true EA201690199A1 (ru) 2018-01-31

Family

ID=52280043

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690199A EA201690199A1 (ru) 2013-07-10 2014-07-09 Лекарственное средство для лечения неалкогольной жировой болезни печени

Country Status (17)

Country Link
US (1) US20160136138A1 (ru)
EP (1) EP3020401B1 (ru)
JP (1) JP6391572B2 (ru)
KR (1) KR102034703B1 (ru)
CN (2) CN105307652A (ru)
AU (1) AU2014288272B2 (ru)
CA (1) CA2917489C (ru)
EA (1) EA201690199A1 (ru)
ES (1) ES2772754T3 (ru)
HK (1) HK1218078A1 (ru)
IL (1) IL243481B (ru)
MX (1) MX2016000307A (ru)
NZ (1) NZ716421A (ru)
PL (1) PL3020401T3 (ru)
PT (1) PT3020401T (ru)
TW (1) TWI696462B (ru)
WO (1) WO2015005365A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
AU2016229982B2 (en) * 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
BR112018074452A2 (pt) * 2016-06-03 2019-03-19 Chemocentryx, Inc. método de tratamento de fibrose hepática
JP2019059673A (ja) * 2016-08-25 2019-04-18 興和株式会社 Ｐｂｃの治療剤
CA3047716A1 (en) * 2017-01-11 2018-07-19 Kowa Company, Ltd. Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
CA3055581C (en) 2017-03-28 2023-03-14 Gilead Sciences, Inc. Methods of treating liver disease
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
CN110831591A (zh) * 2017-06-30 2020-02-21 兴和株式会社 医药组合物
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
KR20200021481A (ko) 2017-06-30 2020-02-28 교와 가부시키가이샤 의약품
JP7402687B2 (ja) * 2017-06-30 2023-12-21 興和株式会社 医薬組成物
US20200121648A1 (en) * 2017-06-30 2020-04-23 Kowa Company, Ltd. Pharmaceutical composition
JPWO2019004452A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
US20200113873A1 (en) * 2017-06-30 2020-04-16 Kowa Company, Ltd. Medicament
EP3646864A4 (en) 2017-06-30 2021-03-17 Kowa Company, Ltd. PEMAFIBRATE MEDICINAL PRODUCT
US11759456B2 (en) 2017-06-30 2023-09-19 Kowa Company, Ltd. Pharmaceutical composition
JP6959049B2 (ja) * 2017-06-30 2021-11-02 興和株式会社 新規低アルブミン血症改善薬
WO2019071216A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
US20220054458A1 (en) 2018-12-27 2022-02-24 Kowa Company, Ltd. Pharmaceutical preparation
JP7071538B2 (ja) 2018-12-27 2022-05-19 興和株式会社 医薬組成物
AU2022282651A1 (en) 2021-05-27 2023-12-07 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease
WO2024010030A1 (ja) * 2022-07-06 2024-01-11 興和株式会社 血中マイオスタチン低下剤
WO2024014524A1 (ja) * 2022-07-15 2024-01-18 興和株式会社 血中ｌｄｌコレステロール低下剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661890B1 (en) 2003-09-03 2011-01-05 Kowa Co., Ltd. Ppar-activating compound and pharmaceutical composition containing same
ZA200601272B (en) * 2003-09-03 2007-04-25 Kowa Co PPAR-activating compound and pharmaceutical composition containing same
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
ES2559238T3 (es) * 2009-09-28 2016-02-11 Kowa Company, Ltd. Agente para reducir el peso de la grasa visceral
CA2790914A1 (en) * 2010-03-24 2011-09-29 Dong-A Pharm. Co., Ltd. Pharmaceutical composition comprising dipeptidyl peptibase-iv inhibitor for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
KR20130113921A (ko) * 2010-05-19 2013-10-16 코와 가부시키가이샤 비알코올성 지방성 간염의 예방 및/또는 치료제
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations

Also Published As

Publication number Publication date
CN114848637A (zh) 2022-08-05
HK1218078A1 (zh) 2017-02-03
CA2917489A1 (en) 2015-01-15
KR20160030479A (ko) 2016-03-18
EP3020401B1 (en) 2019-11-13
IL243481B (en) 2020-01-30
PL3020401T3 (pl) 2020-05-18
EP3020401A4 (en) 2017-02-15
IL243481A0 (en) 2016-02-29
KR102034703B1 (ko) 2019-10-21
CN105307652A (zh) 2016-02-03
MX2016000307A (es) 2016-05-05
JPWO2015005365A1 (ja) 2017-03-02
TWI696462B (zh) 2020-06-21
US20160136138A1 (en) 2016-05-19
PT3020401T (pt) 2020-02-21
ES2772754T3 (es) 2020-07-08
WO2015005365A1 (ja) 2015-01-15
AU2014288272A1 (en) 2016-01-21
AU2014288272B2 (en) 2019-09-19
CA2917489C (en) 2021-05-04
JP6391572B2 (ja) 2018-09-19
TW201536283A (zh) 2015-10-01
NZ716421A (en) 2020-02-28
EP3020401A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
EA201690199A1 (ru) Лекарственное средство для лечения неалкогольной жировой болезни печени
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201890386A1 (ru) Ингибитор мутированной изоцитратдегидрогеназы idh1 r132h
BR112015022197A2 (pt) tratamento de cataplexia
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201691134A1 (ru) Новые ингибиторы глутаминазы
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
EA200900959A1 (ru) Ингибиторы мек
GT201500334A (es) Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70